Elsevier

Cancer Treatment Reviews

Volume 93, February 2021, 102136
Cancer Treatment Reviews

Anti-tumour Treatment
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer

https://doi.org/10.1016/j.ctrv.2020.102136Get rights and content

Highlights

  • Resistance to CDK4/6 inhibitors is a clinical issue in metastatic breast cancer.

  • Predictive biomarkers are eagerly awaited to personalize treatment strategies.

  • Treatments after progression on CDK4/6 inhibitors are yet to be standardized.

  • New strategies are being explored in ongoing clinical trials.

Abstract

CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy are the mainstay of treatment for patients with hormone receptor-positive, HER2 negative (HR+/HER2neg) metastatic breast cancer. However, resistance - either de novo or acquired - invariably occurs, leading to treatment failure and cancer progression. Genomic alterations, gene expression data and circulating biomarkers have been correlated to response to treatment, but to date no biomarker has been approved to stratify patients. Treatment strategies after progression on CDK4/6i are yet to be standardized. Current approaches include endocrine therapy alone or in combination with target therapy, or chemotherapy. New agents are in clinical development based on potential mechanisms of acquired resistance. Here we will review recent advancements in biomarkers of response to CDK4/6i, and in post- treatment therapeutic strategies.

Introduction

Approximately 70% of breast cancers (BC) are hormone receptor (HR)-positive and are reliant on estrogen receptor (ER) signaling for cell proliferation and growth. Endocrine treatments, including aromatase inhibitors (AIs), selective ER modulators (SERMs) and selective ER degraders (SERDs), have formed a mainstay of therapy for patients with HR+ and HER2 negative (HR+/HER2neg) BC [1]. Currently, in metastatic breast cancer (MBC), endocrine therapy (ET) is increasingly administered in combination with inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i), given the impressive results of landmark phase III clinical trials [2], [3], [4], [5], [6], [7], [8], [9], [10]. Briefly, PALOMA-1 and PALOMA-2, MONALEESA-2 and MONARCH-3 investigated the addition of CDK4/6i to AIs in patients not previously treated for MBC [2], [3], [7], [8]. PALOMA-3, MONALEESA-3 and MONARCH-2 investigated the addition of CDK4/6i to fulvestrant mostly in patients progressed on a previous line of ET [4], [6], [9], [11]. MONALEESA-7 demonstrated the efficacy of ribociclib plus ET in premenopausal women [5], [10]. Collectively, these studies demonstrated that the addition of CDK4/6i to AIs or fulvestrant in the first-line and second-line settings led to prolonged progression free survival (PFS) and in some instances, overall survival (OS) [12], [13], [14] compared to ET alone, leading to a change in clinical practice in the management of MBC. There is also some evidence in favor of CDK4/6i as monotherapy. MONARCH-1 assessed single-agent abemaciclib in women with refractory HR+/HER2neg MBC [5]. TREnd randomized patients with endocrine-resistant BC to receive palbociclib alone or in combination to the ET upon which their disease progressed in the previous line [15]. In the neoadjuvant setting, NeoPalAna and neoMONARCH assessed the anti-proliferative activity of palbociclib and abemaciclib, respectively, in primary BC [11], [16]. The results of PENELOPE-B (NCT01864746), which examines patients with high-risk early BC with residual disease following neoadjuvant therapy, are anticipated. A recent efficacy and futility analysis of PALLAS (NCT02513394), a multicentre Phase III trial comparing palbociclib plus adjuvant ET versus adjuvant ET alone, suggested it was unlikely to demonstrate a significant improvement in the primary endpoint of invasive disease-free survival (IDFS) [17]. Contrastingly, the Phase III monarchE study (NCT03155997) demonstrated a statistically significant improvement in IDFS for adjuvant abemaciclib plus ET versus ET alone in high-risk, node-positive early disease [18].

Fig. 1 schematically illustrates the complex axis involving CDK4/6 that leads to the progression of cell cycle from G1 to S phase. CDK4 and 6 bind to the D-type cyclins and phosphorylate and inactivate the retinoblastoma protein (Rb). This event allows the transcription factors E2Fs to be released and to bind to DNA, promoting the expression of genes necessary for S phase entry [19]. In HR+ BC, estrogen is one of the proliferative stimuli that activate this axis; ER mediates cyclin D1 expression and thus the subsequent formation of the cyclin-CDK complex [20]. The CDK4/6 pathway is often deregulated in HR+ BC, due to the amplification of CCND1 gene and/or the over-expression of cyclin D1 protein, with Rb usually being retained [21]. These characteristics make CDK4/6 a logical therapeutic target for treating patients with HR+ BC.

Despite significant survival gains via CDK4/6i therapy for patients with HR+/HER2neg MBC, approximately 15% of those patients with CDK4/6i plus an AI, and up to 30% of those treated with CDK4/6i plus fulvestrant, will develop recurrent disease within six months, denoting de novo resistance. Additionally, virtually all patients with MBC will eventually develop progressive disease due to acquired resistance. Mechanisms of resistance are complex, and still poorly understood in terms of underlying biological processes [22], [23]. Many pathways, including growth factor signaling, the Hippo signaling pathway and the immune system have been implicated in CDK4/6i resistance (Fig. 1). Within these pathways, potential biomarkers of de novo and acquired resistance and therapeutic targets to overcome it have been identified.

Here we will review the recent advancements in biomarkers discovery for CDK4/6i and the potential therapeutic strategies after progression on CDK4/6i in HR+/HER2neg MBC. An overview of the seminal clinical trials investigating CDK4/6i in HR+/HER2neg BC that included translational studies as described in this review is reported in Table 1.

Section snippets

Genomic alterations

Genomic alterations have been largely investigated for their association with CDK4/6i response, both in clinical trials and in retrospective cohorts. The majority of the studies have been performed on circulating tumor DNA (ctDNA), a fraction of cell-free DNA found in the blood of patients with cancer [24].

PIK3CA and ESR1 are among the most commonly mutated genes in HR+/HER2neg, endocrine-resistant MBC [25]. Hence studies have focused on the associations between alterations in these genes and

Acquired resistance and subsequent therapies

In MBC, acquired resistance to CDK4/6 inhibitors occurs as a near-inevitability, and patients thereby require further treatment in subsequent lines.

Data from clinical trials [12], [13], [14], [58], [59] and real-world treatment strategies [60], [61], [62] show the most common treatments after progression on CDK4/6i include chemotherapy or ET, as monotherapy or combined with targeted agents (most commonly the mTOR inhibitor everolimus).

A schematic view of the median duration of subsequent lines

Conclusions

Despite remarkable and concentrated efforts to identify potential genomic drivers of de novo CDK4/6i resistance, to date none of these markers demonstrated clinical utility. While the majority of expression data seems to point to a role of cyclin E1 and the E2F pathway in CDK4/6i response, the collective data are still not concordant. Circulating biomarkers are promising, but require further validation. Current therapeutic strategies after progression on CDK4/6i include chemotherapy and ET,

Declaration of Competing Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [I Migliaccio, M Bonechi, A McCartney, C Guarducci: None. M Benelli: Consultant honoraria: Novartis. L Biganzoli: Personal financial interests (honoraria, consulting or advisory role): AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, Genomic Health, Ipsen, Lilly, Novartis, Pfizer, Pierre Fabre, Roche, Takeda. Institutional financial interests: Celgene, Genomic

Acknowledgements

This work was supported by Fondazione AIRC per la ricerca sul cancro (IG 22869 and MFAG 18880 to L Malorni and MFAG 14371 to I Migliaccio) and Pfizer via an Investigator Initiated Research Grant (to L Malorni) sponsored by “Fondazione Sandro Pitigliani per la lotta contro i tumori” ONLUS. A McCartney is supported by the Fondazione Sandro Pitigliani. This work was also supported by a grant from the Breast Cancer Research Foundation (grant number BCRF 19-037).

Author contribution

Conception and design of the study/ acquisition of data/ analysis and interpretation of data: I Migliaccio, M Bonechi, A McCartney, L Malorni. Drafting and revising the article: I Migliaccio, M Bonechi, L Malorni. Revising the article critically for important intellectual content: A McCartney, C Guarducci, M Benelli, L Biganzoli, A Di Leo. Final approval of the version to be submitted: all authors.

References (99)

  • R.S. Finn et al.

    Palbociclib and letrozole in advanced breast cancer

    New England J Med

    (2016)
  • N.C. Turner et al.

    Palbociclib in hormone-receptor-positive advanced breast cancer

    New England J Med

    (2015)
  • M.N. Dickler et al.

    MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer

    Clin Cancer Res: Off J Am Assoc Cancer Res

    (2017)
  • G.W. Sledge et al.

    MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy

    J Clin Oncol: Off J Am Soc Clin Oncol

    (2017)
  • M.P. Goetz et al.

    MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

    J Clin Oncol: Off J Am Soc Clin Oncol

    (2017)
  • G.N. Hortobagyi et al.

    Ribociclib as first-line therapy for HR-positive, advanced breast cancer

    New England J Med

    (2016)
  • D.J. Slamon et al.

    Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3.

    J Clin Oncol: Off J Am Soc Clin Oncol

    (2018)
  • D. Tripathy et al.

    Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Lancet Oncol

    (2018)
  • C.X. Ma et al.

    NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer

    Clin Cancer Res: Off J Am Assoc Cancer Res

    (2017)
  • G.W. Sledge et al.

    The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial

    JAMA Oncol

    (2019)
  • S.A. Im et al.

    Overall survival with ribociclib plus endocrine therapy in breast cancer

    New England J Med

    (2019)
  • D.J. Slamon et al.

    Overall survival with ribociclib plus fulvestrant in advanced breast cancer

    New England J Med

    (2020)
  • L. Malorni et al.

    Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

    Ann Oncol: Off J Eur Soc Med Oncol/ESMO

    (2018)
  • S.A. Hurvitz et al.

    Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase II neoadjuvant study in HR(+)/HER2(-)

    Breast Cancer.

    (2020)
  • S.R.D. Johnston et al.

    Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, Node-Positive, High-Risk

    Early Breast Cancer (monarchE)

    (2020)
  • S.A. Henley et al.

    The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle

    Cell Div

    (2012)
  • E.A. Musgrove et al.

    Cyclin D as a therapeutic target in cancer

    Nat Rev Cancer

    (2011)
  • Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70. doi:...
  • C. Guarducci et al.

    Mechanisms of resistance to CDK4/6 inhibitors in breast cancer and potential biomarkers of response

    Breast care (Basel, Switzerland).

    (2017)
  • A. McCartney et al.

    Mechanisms of resistance to CDK4/6 inhibitors: potential implications and biomarkers for clinical practice

    Front Oncol

    (2019)
  • T.K.Y. Tay et al.

    Liquid biopsy in breast cancer: a focused review

    Arch Pathol Lab Med

    (2020)
  • P. Razavi et al.

    The genomic landscape of endocrine-resistant advanced breast cancers

    Cancer Cell

    (2018)
  • C. Fribbens et al.

    Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer

    J Clin Oncol: Off J Am Soc Clin Oncol.

    (2016)
  • M. Cristofanilli et al.

    Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

    Lancet Oncol

    (2016)
  • B. O'Leary et al.

    Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

    Nat Commun

    (2018)
  • Tolaney SM, Toi M, Neven P, Sohn J, Grischke E-M, Llombart-Cussac A, et al. Abstract 4458: Clinical significance of...
  • Neven P, Petrakova K, Val Bianchi G, De la Cruz-Merino L, Jerusalem G, Sonke G, et al. Abstract PD2-05: Biomarker...
  • Z. Li et al.

    Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway

    Cancer Cell

    (2018)
  • F. Andre et al.

    Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials

    J Clin Oncol

    (2020)
  • B. O'Leary et al.

    Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer

    J Natl Cancer Inst

    (2020)
  • Formisano L, Lu Y, Servetto A, Hanker AB. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+...
  • De Laurentiis M, Malorni L, Bianchini G, Caputo R, Giuliano M, Zambelli A, et al. Abstract P5-01-07: Bioitalee -...
  • Wander SA, Cohen O, Gong X, Johnson GN, Buendia-Buendia JE, Lloyd MR. The genomic landscape of intrinsic and acquired...
  • N.C. Turner et al.

    Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer

    J Clin Oncol: Off J Am Soc Clin Oncol

    (2019)
  • Finn RS, Liu Y, Zhu Z, Martin M. Biomarker analyses of response to cyclin-dependent kinase 4/6 inhibition and endocrine...
  • G.N. Hortobagyi

    Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial

    Breast Cancer Res: BCR

    (2018)
  • A. Di Leo et al.

    Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

    npj Breast Cancer

    (2018)
  • I. Doostan et al.

    Cytoplasmic cyclin E mediates resistance to aromatase inhibitors in breast cancer

    Clin Cancer Res

    (2017)
  • Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, et al. CDK4/6 and autophagy inhibitors synergistically...
  • Cited by (0)

    View full text